文献速递脊柱关节炎

纵向队列中晚发型银屑病关节炎:疾病表现、随时间活动度及预后

Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis.
PubMed 文献 · Semin Arthritis Rheum · 2018-08-24

该前瞻性纵向队列纳入566例诊断后2年内随访的银屑病关节炎患者,比较晚发型(起病≥50岁,LoPsA)与早发型(起病<50岁,YoPsA)的表现与5年预后;LoPsA初诊时女性更多、BMI更高、损害更重且HLA-C*06更少,5年后疾病活动负担有升高趋势且损害显著更多。

要点

  • 晚发型银屑病关节炎初诊特征:男性更少、HLA-C*06更少、银屑病病程更长、BMI更高、mSS更高。
  • 随访5年,LoPsA组平均mSS评分显著更高,活动关节数有升高趋势但未达统计学显著。
  • 随访5年间YoPsA组NSAIDs使用更多(96% vs 88%,p=0.04),DMARDs与生物制剂无显著差异。

核心结论

  • 晚发型银屑病关节炎患者初诊时以女性为主、BMI更高、损害更多且HLA-C*06更少;随访5年后预后更差,表现为疾病活动负担有升高趋势且损害显著更多。

研究设计与样本

  • 前瞻性纵向队列研究,纳入诊断后2年内随访的银屑病关节炎患者566例,按起病年龄分为晚发型(起病≥50岁)与早发型(起病<50岁),采用描述性统计与多变量逻辑回归模型比较两组。

主要发现

  • 初诊时回归分析显示LoPsA组男性更少(OR 0.4,p=0.001)、HLA-C*06更少(OR 0.3,p=0.005)、银屑病病程更长(OR 1.04,p=0.0005)、BMI更高(OR 1.1,p=0.005)、改良Steinbrocker评分(mSS)更高(OR 1.1,p=0.005)。
  • 随访5年、校正性别、BMI、银屑病病程、HLA及治疗后,LoPsA组较YoPsA组调整后平均活动关节数有升高趋势(OR 7.98,p=0.052),平均mSS评分更高(OR 13.39,p=0.007)。
  • 随访5年间,YoPsA组NSAIDs使用更多(96% vs 88%,p=0.04),DMARDs与生物制剂使用无显著差异。

关键数值与推荐

  • 晚发型银屑病关节炎定义为疾病起病年龄≥50岁,早发型定义为起病年龄<50岁。
  • 初诊时LoPsA组较YoPsA组:男性OR 0.4(p=0.001),HLA-C*06 OR 0.3(p=0.005),银屑病病程OR 1.04(p=0.0005),BMI OR 1.1(p=0.005),mSS OR 1.1(p=0.005)。
  • 随访5年LoPsA组较YoPsA组:调整后平均活动关节数OR 7.98(p=0.052),平均mSS评分OR 13.39(p=0.007)。
  • 随访5年间NSAIDs使用:YoPsA组96% vs LoPsA组88%(p=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate disease activity of late onset psoriatic arthritis (LoPsA) patients at presentation, during follow-up, and after 5years of follow-up, compared to young onset PsA patients (YoPsA). METHODS: The study included patients with PsA followed prospectively within 2years from diagnosis. Patients were divided into two groups: (1) LoPsA - defined as disease onset ≥ 50 years, (2) YoPsA - defined as disease onset < 50 years. Descriptive statistics are provided and multivariable logistic regression models were developed to compare these groups. RESULTS: Five hundred and sixty-six patients were included at presentation. Regression analysis showed that the LoPsA group at presentation was characterized by: less males (OR 0.4, p = 0.001), less HLA-C*06 (OR 0.3, p = 0.005), longer psoriasis duration (OR 1.04, p = 0.0005), higher BMI (OR 1.1, p = 0.005) and higher modified Steinbrocker score (mSS) (OR 1.1, p = 0.005). Regression analysis adjusted for gender, BMI, psoriasis duration, HLA and treatments after 5years of follow-up revealed a trend toward higher adjusted mean active joint count (OR 7.98, p = 0.052) and higher mean mSS score (OR 13.39, p = 0.007) in the LoSpA group compared to the YoPsA group. During 5years of follow-up, the YoPsA patients were treated with more NSAIDs (96% vs. 88%, p = 0.04), while there were no significant differences in the DMARDs and biologic drugs. CONCLUSION: The LoPsA patients at presentation are characterized by female predominance, higher BMI, more damage and less HLA-C*06. After 5years of follow-up the LoPsA patients have worse prognosis manifested by a trend toward higher disease activity burden and significantly more damage.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Polachek A, Al-Johani R, Li S, et al. Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Semin Arthritis Rheum. 2018. PMID: 30243758. doi:10.1016/j.semarthrit.2018.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。